Application of streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet in preparation of product for treating oral ulcer

Abstract

The invention discloses an application of a streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet in preparation of a product for treating oral ulcer. The preservation number of the streptococcus salivarius subsp. Thermophilus Biohalo 23 is DSM34540; the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention can reduce the morbidity of oral ulcer, relieve pain symptoms and shorten the morbidity cycle, so that the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention has a remarkable curative effect on the oral ulcer, and particularly, clinical tests prove that the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet has a remarkable curative effect on the oral ulcer. The streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention can be used for remarkably reducing the morbidity of the oral ulcer, reducing the pain of the oral ulcer and shortening the recovery period of the oral ulcer, so that the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention can be used for treating the oral ulcer.

Description

Technical Field

[0001] The invention relates to the technical field of probiotics, and in particular to application of a Streptococcus salivarius thermophilic subspecies Biohalo23 tablet in the preparation of a product for treating oral ulcers. Background Art

[0002] Oral ulcers, also known as "mouth sores", are a common oral mucosal disease that often appears on the mucosa of the lips, palate, tongue and cheeks in the mouth. They are round or oval painful ulcers. Various factors such as genetics, diet, and decreased immunity may induce the development of oral ulcers, which vary greatly from person to person. 10% to 25% of the population suffers from recurrent oral ulcers, which are common in the 10 to 30-year-old group, and the prevalence rate in women is higher than that in men.

[0003] Oral ulcers can appear on the mucous membranes of the lips, cheeks, soft palate or gums in the mouth. The ulcer surface is round or oval, with a white or yellow center, slightly red and swollen surrounding congestion, and accompanied by obvious pain.

[0004] Oral ulcers are cyclical, recurrent, and self-limiting. Although oral ulcers can cause discomfort, the prognosis is generally good. They usually heal on their own in about a week, and often leave no scars. Nutritional supplements such as vitamin C and B vitamins, as well as measures such as ensuring adequate rest and avoiding excessive fatigue, can all help prevent the occurrence of oral ulcers.

[0005] At present, the treatment measures for oral ulcers are mainly local anti-inflammatory, pain relief, and promotion of ulcer healing. Systemic treatment mostly prolongs the interval period. Treatment is based on the severity of the ulcer and the patient's wishes. The main methods include local drug therapy, systemic drug therapy, and physical therapy. Laser irradiation can help mucosal regeneration, reduce inflammatory response, and promote ulcer healing. Drug treatment includes anti-inflammatory drugs, analgesics, and healing-promoting drugs, but these drugs only treat the symptoms and not the root cause, and are prone to adverse reactions during use.

[0006] In view of this, the present invention is proposed. Summary of the invention

[0007] The object of the present invention is to provide an application of a thermophilic Streptococcus salivarius subsp. Biohalo23 tablet in the preparation of a product for treating oral ulcers. The thermophilic Streptococcus salivarius subsp. Biohalo23 tablet of the present invention can reduce the incidence of oral ulcers, relieve pain symptoms and shorten the onset period. Therefore, the thermophilic Streptococcus salivarius subsp. Biohalo23 tablet of the present invention has a significant therapeutic effect on oral ulcers.

[0008] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0009] A first aspect of the present invention provides an application of a Streptococcus salivarius thermophilus subspecies Biohalo23 tablet in the preparation of a product for treating oral ulcers, wherein the Streptococcus salivarius thermophilus subspecies Biohalo23 has a deposit number of DSM34540.

[0010] The second aspect of the present invention provides a probiotic tablet, which comprises the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials.

[0011] Preferably, the content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

[0012] Preferably, the auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

[0013] Preferably, the auxiliary materials consist of 10-15 parts of crystalline fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

[0014] Preferably, the flavor includes strawberry flavor, apple flavor or orange flavor.

[0015] Preferably, the mass of each probiotic tablet is 0.9-1 g.

[0016] Compared with the prior art, the beneficial effects of the present invention include at least:

[0017] The thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can reduce the incidence of oral ulcers, relieve pain symptoms and shorten the onset period. Therefore, the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention have significant therapeutic effects on oral ulcers. Specifically, through clinical trials, the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can significantly reduce the incidence of oral ulcers, and at the same time can reduce the pain of oral ulcers and shorten the recovery period of oral ulcers, thereby indicating that the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can be used for the treatment of oral ulcers.

[0018] In addition, the thermophilic subspecies Biohalo23 tablets of Streptococcus salivarius of the present invention are easy to take and can ensure that the probiotics are stable and active for a long time. At the same time, the special tablets have a stable melting speed, melting in the mouth in about 3-5 minutes, ensuring that there is enough time for the thermophilic subspecies Biohalo23 strain of Streptococcus salivarius to colonize in the oropharynx. However, other dosage forms have poor therapeutic effects, such as liquid preparations, which quickly reach the stomach and intestines when taken, causing the death of a large number of bacteria in the gastrointestinal environment, and fewer strains are colonized in the oropharynx, resulting in failure to achieve effective therapeutic effects. DETAILED DESCRIPTION

[0019] The following embodiments of the technical solution of the present invention are described in detail in conjunction with the embodiments. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and are therefore only used as examples, and cannot be used to limit the protection scope of the present invention.

[0020] It should be noted that, unless otherwise specified, the technical terms or scientific terms used in this application should have the common meanings understood by those skilled in the art to which the present invention belongs.

[0021] The embodiment of the present invention provides an application of a Streptococcus salivarius thermophilus subspecies Biohalo23 tablet in preparing a product for treating oral ulcers, wherein the Streptococcus salivarius thermophilus subspecies Biohalo23 has a deposit number of DSM34540.

[0022] The preservation unit of the thermophilic subspecies Biohalo23 of Streptococcus salivarius of the present invention is the German Microorganisms Preservation Center, and the strain can be purchased from the German Microorganisms Preservation Center.

[0023] The thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can reduce the incidence of oral ulcers, relieve pain symptoms and shorten the onset period. Therefore, the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention have significant therapeutic effects on oral ulcers. Specifically, through clinical trials, the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can significantly reduce the incidence of oral ulcers, and at the same time can reduce the pain of oral ulcers and shorten the recovery period of oral ulcers, thereby indicating that the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can be used for the treatment of oral ulcers.

[0024] In addition, the thermophilic subspecies Biohalo23 tablets of Streptococcus salivarius of the present invention are easy to take and can ensure that the probiotics are stable and active for a long time. At the same time, the special tablets have a stable melting speed, melting in the mouth in about 3-5 minutes, ensuring that there is enough time for the thermophilic subspecies Biohalo23 strain of Streptococcus salivarius to colonize in the oropharynx. However, other dosage forms have poor therapeutic effects, such as liquid preparations, which quickly reach the stomach and intestines when taken, causing the death of a large number of bacteria in the gastrointestinal environment, and fewer strains are colonized in the oropharynx, resulting in failure to achieve effective therapeutic effects.

[0025] Another embodiment of the present invention provides a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials.

[0026] By adding auxiliary materials, the activity of the thermophilic subspecies of Streptococcus salivarius Biohalo23 can be better preserved, and the taste of the product can be improved, thereby improving the taste of the probiotic tablets for children.

[0027] In one embodiment, the content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

[0028] By limiting the content of the thermophilic subspecies Biohalo23 of Streptococcus salivarius in probiotic tablets, the efficacy of the probiotic tablets can be better improved.

[0029] In one embodiment, the auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

[0030] In some embodiments, the auxiliary materials are composed of 10-15 parts of crystalline fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

[0031] In one embodiment, the flavor includes strawberry flavor; in other embodiments, the flavor may be strawberry flavor, apple flavor or orange flavor.

[0032] In one embodiment, the mass of each probiotic tablet is 0.9-1 g.

[0033] The technical scheme of the present invention is further described in detail below through specific examples. The various materials and reagents used in the following specific examples are commonly used materials and reagents in the field and can be obtained through regular commercial channels; the methods used are conventional methods known to those skilled in the art.

[0034] Example 1

[0035] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0036] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0037] The auxiliary materials consist of 10 parts of crystalline fructose, 88 parts of maltodextrin, 0.8 parts of magnesium stearate and 0.2 parts of flavor, wherein the flavor is strawberry flavor.

[0038] Example 2

[0039] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0040] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0041] The auxiliary materials consist of 15 parts of crystalline fructose, 82 parts of maltodextrin, 1.2 parts of magnesium stearate and 0.8 parts of flavor, wherein the flavor is strawberry flavor.

[0042] Example 3

[0043] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0044] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0045] The auxiliary materials consist of 12 parts of crystalline fructose, 85.5 parts of maltodextrin, 1 part of magnesium stearate and 0.5 parts of flavor, wherein the flavor is strawberry flavor.

[0046] Experimental example

[0047] This experimental example is a study on the effect of Streptococcus salivarius thermophilus subspecies Biohalo23 (German strain library deposit number DSM34540) on oral ulcers;

[0048] The probiotic tablets used in the following experiments are the probiotic tablets prepared in Example 3.

[0049] A total of 163 patients with recurrent oral ulcers were recruited for the experiment, of which 87 patients took probiotic tablets for 30 days, one tablet per day; 76 patients did not take oral medication as the control group and were followed up for 60 days.

[0050] Experimental results:

[0051] Compared with the control group, the incidence of oral ulcers decreased by 52% during the period when patients took the probiotic tablets;

[0052] Compared with the control group, the incidence of oral ulcers in patients during the follow-up period decreased by 77%.

[0053] In summary, taking probiotic tablets can significantly reduce the incidence of oral ulcers, reduce the pain of oral ulcers and shorten the recovery period of oral ulcers, which further indicates that the thermophilic subspecies of Streptococcus salivarius Biohalo23 tablets of the present invention can be used for the treatment of oral ulcers.

[0054] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

Claims

1. Application of Streptococcus salivarius thermophilus subspecies Biohalo23 tablets in the preparation of products for treating oral ulcers, characterized in that: The thermophilic Streptococcus salivarius subspecies Biohalo23 is deposited with DSM34540.

2. A probiotic tablet, characterized in that: The probiotic tablet comprises the thermophilic Streptococcus salivarius subspecies Biohalo23 according to claim 1 and auxiliary materials.

3. The probiotic tablet according to claim 2, characterized in that The content of the thermophilic Streptococcus salivarius subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

4. The probiotic tablet according to claim 2, characterized in that The auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

5. The probiotic tablet according to claim 2, characterized in that: The auxiliary material consists of 10-15 parts of crystal fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

6. The probiotic tablet according to claim 4, characterized in that: The flavor includes strawberry flavor, apple flavor or orange flavor.

7. The probiotic tablet according to claim 2, characterized in that: The mass of each probiotic tablet is 0.9-1g.